Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02034058 · ClinicalTrials.gov registry record · NA
Post Market Surveillance Study of the Wingspan Stent System
A NA study, sponsored by Stryker Neurovascular.
- Completed
- Registry status
- NA
- Development phase
- 152
- Enrollment target
NCT02034058: Completed NA study, sponsored by Stryker Neurovascular.
NCT02034058 is a NA study that has completed, run by Stryker Neurovascular. The registered enrollment target is 152 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02034058, a NA study, has completed, sponsored by Stryker Neurovascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 152 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the rate of stroke and/or death in patients treated with the Wingspan Stent System, according to the Indications for Use, within 72 hours post procedure.
Primary Outcome
The primary endpoint in this study is the rate of stroke (ischemic or hemorrhagic) or death within 72 hours of the procedure. Ischemic stroke was defined as a neurological deficit that is thought to have an ischemic cause and is detectable on examination at least 24 hours after onset of symptoms. Hemorrhagic stroke was defined as a symptomatic intracerebral, subarachnoid, or primary intraventricular hemorrhage. The type of stroke was confirmed by imaging.
Interventions
- DEVICE Wingspan Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2013-12 |
| Est. Completion | 2019-08 |
| Phase | NA |
What the finished NCT02034058 record still lists
NCT02034058 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Wingspan Stent System is the first listed.
NCT02034058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02034058 about?
NCT02034058 is a clinical study titled "Post Market Surveillance Study of the Wingspan Stent System". The primary objective of this study is to evaluate the rate of stroke and/or death in patients treated with the Wingspan Stent System, according to the Indications for Use, within 72 hours post procedure.
What is the current status of trial NCT02034058?
This trial is currently completed. It is a NA study. The enrollment target is 152 participants. The study started on 2013-12. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02034058?
The interventions under investigation include: Wingspan Stent System (DEVICE).
Who is sponsoring clinical trial NCT02034058?
This trial is sponsored by Stryker Neurovascular, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02034058's enrollment target sits among peer trials
152 658th of 2000 higher than 1,340 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia